戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 aired learning and memory in dementia of the Alzheimer type.
2 ysiological event underlying dementia of the Alzheimer type.
3 L-40 levels in controls with dementia of the Alzheimer type.
4 ysiological event underlying dementia of the Alzheimer type.
5  NFT typical of the amnestic dementia of the Alzheimer type.
6 es with the typical amnestic dementia of the Alzheimer type.
7 sk may help to prevent dementia, even of the Alzheimer type.
8 formance in patients with senile dementia of Alzheimer type.
9 ance in the pathogenesis of dementias of the Alzheimer type.
10 e impairment due to incipient demenia of the Alzheimer type.
11   Alzheimer's disease/senile dementia of the Alzheimer type (AD/SDAT) is the most common neuropatholo
12 xpression with PS1dE9 caused mice to develop Alzheimer-type amyloid pathology by 24 months of age.
13 s on phenotypes related to the deposition of Alzheimer-type amyloid.
14 es have not been observed in mice that model Alzheimer-type amyloidosis by expressing mutant amyloid
15                In transgenic mice that model Alzheimer-type amyloidosis, we sought to determine wheth
16 rican-American patients with dementia of the Alzheimer type and 50 age-matched controls (cases vs con
17 ples from 208 white cases of dementia of the Alzheimer type and from 185 age-matched controls (mean a
18 l lysates from patients with dementia of the Alzheimer type and nondemented patients with Abeta plaqu
19 is in any of these systems and the degree of Alzheimer type brain pathology.
20 xamined the relationship between neocortical Alzheimer-type brain pathology and dementia in consecuti
21 ts with ALS or controls with dementia of the Alzheimer type, but they did correlate with tau, phospho
22 changes such as cortical atrophy, as well as Alzheimer-type changes on functional imaging and in cere
23 lder adults with early-stage dementia of the Alzheimer type (DAT) (n = 23) were imaged while alternat
24 e clinical manifestations of dementia of the Alzheimer type (DAT) by many years and can be associated
25 unusually high prevalence of dementia of the Alzheimer type (DAT) in Wadi Ara, an inbred Arab communi
26 band frequency of Abeta peptides in Dementia Alzheimer type (DAT) patients, which indicated an overal
27 jects with and without early dementia of the Alzheimer type (DAT) were studied by using MRI at 1.0 mm
28 ith a decreased incidence of dementia of the Alzheimer type (DAT), but not with vascular dementia.
29 dults in the early stages of dementia of the Alzheimer type (DAT).
30 adical theory of ageing may also account for Alzheimer-type degeneration and consequently links betwe
31 t motor behavior, which was more frequent in Alzheimer-type dementia (5.4% vs 1%; P =.02).
32        Effects of drug treatment of clinical Alzheimer-type dementia (CATD) are uncertain.
33 ief cognitive tests for identifying clinical Alzheimer-type dementia (CATD) are uncertain.
34  progressive aphasia but not in the amnestic Alzheimer-type dementia (P < 0.05).
35   We studied platelets from 14 patients with Alzheimer-type dementia and 14 non-demented controls mat
36 hirty-three subjects with very mild and mild Alzheimer-type dementia and 21 subjects without dementia
37 ychiatric symptoms between participants with Alzheimer-type dementia and those with other dementias,
38 or delay cognitive decline, MCI, or clinical Alzheimer-type dementia in adults with normal cognition
39     Few studies examined effects on clinical Alzheimer-type dementia or MCI, and those that did sugge
40 recommendation was formulated: screening for Alzheimer-type dementia starting at age 40 years.
41 + efflux from the platelets of patients with Alzheimer-type dementia was not inhibited by either apam
42 ere (usually left), and differs from typical Alzheimer-type dementia where amnesia is the primary def
43 iation of increasing WMH-volume with stroke, Alzheimer-type dementia, and of increasing blood pressur
44 ion of increased [11C](R)-PK11195 binding in Alzheimer-type dementia, including mild and early forms,
45 rate of disease progression in subjects with Alzheimer-type dementia.
46 e rapid disease progression in subjects with Alzheimer-type dementia.
47 sociated with vascular-type dementia but not Alzheimer-type dementia.
48 re for the growing population of people with Alzheimer-type dementia.
49 , some of which are neurotoxic and linked to Alzheimer-type dementia.
50    The prototypic examples of the latter are Alzheimer type dementias.
51     Studies of subjects with dementia of the Alzheimer type have reported correlations between increa
52 nstrate progressive neurodegeneration of the Alzheimer type in these animals.
53 mentia and common neuropathological markers (Alzheimer-type, infarcts and Lewy-body) was modelled, st
54                  Late onset dementias of the Alzheimer type may be coupled to intrinsic aging process
55            In both prion-infected and 5XFAD (Alzheimer-type) mice, the capacity to regenerate synapse
56 tured Interview for Diagnosis of Dementia of Alzheimer Type, Multi-infarct Dementia and Dementia of o
57 ects with very mild and mild dementia of the Alzheimer type (n = 29) and age-matched, cognitively nor
58 oups, SuperAgers showed a lower frequency of Alzheimer-type neurofibrillary tangles (p < 0.05).
59        Cortical involvement of Lewy body and Alzheimer-type pathologies are key features, but multipl
60                   A combination of Lewy- and Alzheimer-type pathologies is a robust pathological corr
61         The relative importance of Lewy- and Alzheimer-type pathologies to dementia in Parkinson's di
62  allele was strongly associated with overall Alzheimer type pathology (all p</=0.001).
63 time that MAPT H1 is associated with reduced Alzheimer type pathology which could have important impl
64 lationship between systemic atherosclerosis, Alzheimer type pathology, and dementia in autopsies from
65 vated in activated astrocytes of brains with Alzheimer type pathology, including sporadic Alzheimer's
66 , 1.97; P = .006]) and higher probability of Alzheimer-type pathology (1.84; P = .02).
67 fficacious therapeutic approach to combating Alzheimer-type pathology in vivo.
68 eimer's disease and significant coincidental Alzheimer-type pathology was also found in one of the ub
69                                              Alzheimer-type pathology was found in the two of the cap
70 rinic receptors is associated with increased Alzheimer-type pathology was investigated in Parkinson's
71                          A unique pattern of Alzheimer-type pathology was observed in the cerebellum:
72                       An association of mild Alzheimer-type pathology with definite cognitive impairm
73  to see if there was an effect of concurrent Alzheimer-type pathology, and the ratio of 4R to 3R tau
74 d capuchin monkeys can spontaneously develop Alzheimer-type pathology, indicating that they may be an
75                 In PSP cases with concurrent Alzheimer-type pathology, the ratio of 4R to 3R was inte
76 ation within muscle fibers of brain-specific Alzheimer type proteins.
77 is study was an investigation of the role of Alzheimer-type senile degenerative abnormalities in the
78 dividuals who have died from dementia of the Alzheimer type show abnormally low densities of nAChRs.
79 volume in very mild and mild dementia of the Alzheimer type, whereas levels of CSF Abeta(42), but not
80 ptoms transdiagnostically in dementia of the Alzheimer type, which is characterized by prominent amne